Who can they bribe this time:
In addition, FDA’s neuroscience chief Billy Dunn, who had a hand in the approval of the previous Duchenne drugs, left the regulatory agency at the end of February. The first Duchenne treatment, Sarepta’s Exondys 51, was approved by the FDA after an advisory committee voted against it.
- Forums
- ASX - By Stock
- PER
- Fresh Start
Fresh Start, page-47
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.92M |
Open | High | Low | Value | Volume |
8.2¢ | 8.2¢ | 8.2¢ | $1.521K | 18.55K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 31160 | 8.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 3424 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 31160 | 0.081 |
1 | 25278 | 0.079 |
2 | 30620 | 0.078 |
1 | 10000 | 0.077 |
3 | 96800 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 3424 | 1 |
0.083 | 100000 | 1 |
0.084 | 160250 | 2 |
0.085 | 168500 | 2 |
0.086 | 291111 | 3 |
Last trade - 11.08am 29/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online